Skip to main content
    A

    Abbott Laboratories (ABT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $104.76
    -2.69 (-2.50%)

    Market Cap: $186.10B

    Last updated: Nov 17, 2026 at 4:42 PM ET

    Abbott Laboratories (ABT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Abbott Laboratories (ABT) has a market cap of $186.10B and an enterprise value of $213.20B. Its trailing P/E is 19.5x.

    Total Valuation

    Enterprise value is 14.57% above the market cap, as debt exceeds cash.

    Market Cap$186.10B
    Enterprise Value$213.20B
    Latest price (Nov 17, 2026)$104.76

    Key Dates

    The next earnings report is expected on Jan 20, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Oct 15, 2026.

    Next Earnings DateJan 20, 2027 (expected)
    Last Earnings DateOct 21, 2026
    Last Ex-Dividend DateOct 15, 2026
    Last Payment DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.34% in the quarter ended Sep 30, 2026 and shrank 0.14% a year over 2 years.

    Shares Outstanding1.73B
    Shares Change (YoY)-0.44%
    Shares Change (QoQ)-0.34%
    Share Count Growth (2Y CAGR)-0.14%

    Valuation Ratios

    Sales and book value multiples are 3.8x and 3.6x. Its year-end P/E ranged from 17.5x to 30.0x from 2016 to 2025.

    P/E Ratio19.5x
    Forward P/E18.8x
    P/S Ratio3.8x
    Forward P/S3.7x
    P/B Ratio3.6x
    P/FCF Ratio26.9x
    P/OCF Ratio21.0x
    PEG Ratio2.1

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 18.7x EBITDA and 30.9x free cash flow.

    EV / Earnings45.4x
    EV / Sales4.4x
    EV / EBITDA18.7x
    EV / EBIT29.3x
    EV / FCF30.9x

    Price Statistics

    The stock is down 19.37% over 52 weeks and trades 1.16% above its 50-day average.

    Beta (1Y)0.10
    52-Week Change-19.37%
    1-Month Change+0.67%
    3-Month Change-7.90%
    6-Month Change+18.78%
    5-Year Change-17.60%
    10-Year Change+170.64%
    Total Return (1Y)-17.43%
    Total Return (3Y CAGR)+3.04%
    Total Return (5Y CAGR)-2.42%
    Return vs SPY (1Y)-30.56%
    Max Drawdown (1Y)-36.63%
    Max Drawdown (3Y)-40.73%
    Sharpe Ratio (1Y)-0.74
    Correlation with SPY (1Y)0.05
    50-Day Average$103.56
    200-Day Average$100.73
    52-Week Range$80.89 to $128.30
    RSI (14 Days)45.9
    Average Volume (20 Days)9.09M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.45x current liabilities, and total debt is 0.61x shareholder equity.

    Current Ratio1.45x
    Quick Ratio1.00x
    Debt / Equity0.61x
    Debt / EBITDA2.79x
    Debt / FCF4.61x
    Interest Coverage7.30x

    Returns and Efficiency

    Return on invested capital is 6.34% over the last 12 months, against a 5-year average of 12.11%.

    Return on Equity (ROE)9.21%
    Return on Assets (ROA)4.34%
    Return on Invested Capital (ROIC)6.34%
    Return on Capital Employed (ROCE)7.89%
    ROE (5Y Average)18.82%
    ROA (5Y Average)10.10%
    ROIC (5Y Average)12.11%
    Asset Turnover0.50x
    Inventory Turnover2.83x
    Receivables Turnover5.47x
    Cash Conversion Cycle112 days

    Taxes

    Income tax took 28.36% of pretax income over the last 12 months.

    Income Tax (TTM)$1.86B
    Effective Tax Rate28.36%

    Scores

    ABT has an Altman Z-Score of 3.32, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score3.32
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $48.23B over the last 12 months is up 10.00% from the 12 months before.

    Revenue$48.23B
    Revenue Growth (YoY)+10.00%
    Gross Profit$27.46B
    Operating Income$6.65B
    Pretax Income$6.56B
    Net Income$4.70B
    EBITDA$11.18B
    EBIT$7.27B
    Reported EPS (TTM)$5.38

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 47.14% of the $108.25B in total assets.

    Cash and Equivalents$4.05B
    Total Debt$31.16B
    Net Debt$27.11B
    Net Debt Per Share$15.63
    Working Capital$7.34B
    Shareholder Equity$51.03B
    Book Value Per Share$29.42
    Tangible Book Value-$1.21B
    Total Assets$108.25B
    Total Liabilities$56.62B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.10B of capital spending, operating cash flow left $6.76B of free cash flow.

    Operating Cash Flow$8.86B
    Capital Expenditures$2.10B
    Free Cash Flow$6.76B
    FCF Per Share$3.90
    Depreciation and Amortization$3.91B
    Dividends Paid$4.32B
    Share Repurchases$1.54B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 13.78%, against a 5-year average of 17.86%.

    Gross Margin56.94%
    Operating Margin13.78%
    Pretax Margin13.61%
    Net Margin9.75%
    EBITDA Margin23.18%
    EBIT Margin15.07%
    FCF Margin14.01%
    Gross Margin (5Y Average)56.03%
    Operating Margin (5Y Average)17.86%
    Net Margin (5Y Average)18.65%

    Growth

    Revenue grew 0.51% a year over 3 years, and EPS fell 1.20% a year.

    Revenue Growth (3Y CAGR)+0.51%
    Revenue Growth (5Y CAGR)+5.08%
    EPS Growth (3Y CAGR)-1.20%
    EPS Growth (5Y CAGR)+7.13%
    FCF Growth (3Y CAGR)-1.78%
    FCF Growth (5Y CAGR)+5.26%
    Operating Income Growth (3Y CAGR)-1.25%
    Book Value Per Share Growth (2Y CAGR)+16.24%
    Tangible Book Per Share Growth (2Y CAGR)+92.26%

    Revenue and profit by year

    Dividends and Yields

    ABT pays out 49.36% of earnings as dividends.

    Dividend Per Share (Annual)$2.52
    Dividend Yield2.41%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+7.87%
    Dividend Growth (5Y CAGR)+10.38%
    Payout Ratio49.36%
    FCF Payout Ratio63.99%
    Earnings Yield5.13%
    FCF Yield3.72%
    Buyback Yield0.85%
    Shareholder Yield3.23%

    Full dividend history

    Peer Position

    Against 10 similar companies, ABT has the 6th highest P/E.

    P/E Ratio19.5x vs 18.8x median
    P/S Ratio3.8x vs 3.9x median
    ROIC6.34% vs 9.82% median
    Revenue Growth (Trailing 4 Quarters, YoY)+10.00% vs +8.14% median
    Dividend Yield2.41% vs 0.57% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.86% and EPS growth at 7.37% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.86%
    EPS Growth Forecast (2Y CAGR)+7.37%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ABT

    What is ABT's market cap?

    Abbott Laboratories has a market cap of $186.10B. Its enterprise value, which adds debt and subtracts cash, is $213.20B.

    What is ABT's P/E ratio?

    Abbott Laboratories has a trailing P/E ratio of 19.5x and a forward P/E of 18.8x.

    How many shares of ABT are outstanding?

    Abbott Laboratories has 1.73B shares outstanding. The count is down 0.44% from a year earlier.

    Does ABT pay a dividend?

    Yes. Abbott Laboratories pays $2.52 a share a year, a dividend yield of 2.41%.

    How much debt does ABT have?

    Abbott Laboratories has $31.16B of total debt and $4.05B of cash and equivalents, a net debt position of $27.11B.